11 research outputs found
Near-ground Effect of Height on Pollen Exposure
The effect of height on pollen concentration is not well documented and little is known about the near-ground
vertical profile of airborne pollen. This is important as most measuring stations are on roofs, but patient
exposure is at ground level. Our study used a big data approach to estimate the near-ground vertical profile
of pollen concentrations based on a global study of paired stations located at different heights. We
analyzed paired sampling stations located at different heights between 1.5 and 50m above ground level (AGL). This provided pollen data from 59 Hirst-type volumetric traps
from 25 different areas, mainly in Europe, but also covering North America and Australia, resulting in about
2,000,000 daily pollen concentrations analyzed. The daily ratio of the amounts of pollen from different heights
per location was used, and the values of the lower station were divided by the higher station. The lower station
of paired traps recorded more pollen than the higher trap. However, while the effect of height on pollen concentration
was clear, it was also limited (average ratio 1.3, range 0.7–2.2). The standard deviation of the pollen
ratio was highly variable when the lower station was located close to the ground level (below 10m AGL). We
show that pollen concentrations measured at >10m are representative for background near-ground levels
Extraction of DNA from lichen-forming and lichenicolous fungi: a low-cost fast protocol using Chelex
Near-ground effect of height on pollen exposure
The effect of height on pollen concentration is not well documented and little is known about the near-ground vertical profile of airborne pollen. This is important as most measuring stations are on roofs, but patient exposure is at ground level. Our study used a big data approach to estimate the near-ground vertical profile of pollen concentrations based on a global study of paired stations located at different heights. We analyzed paired sampling stations located at different heights between 1.5 and 50 m above ground level (AGL). This provided pollen data from 59 Hirst-type volumetric traps from 25 different areas, mainly in Europe, but also covering North America and Australia, resulting in about 2,000,000 daily pollen concentrations analyzed. The daily ratio of the amounts of pollen from different heights per location was used, and the values of the lower station were divided by the higher station. The lower station of paired traps recorded more pollen than the higher trap. However, while the effect of height on pollen concentration was clear, it was also limited (average ratio 1.3, range 0.7–2.2). The standard deviation of the pollen ratio was highly variable when the lower station was located close to the ground level (below 10 m AGL). We show that pollen concentrations measured at >10 m are representative for background near-ground levels
Effect of Height on Pollen Sampling in Relation to Pollen Exposure at Ground Level
Pollen monitoring networks around the world are mainly based on rooftop-located stations on buildings. Thus, measured airborne pollen levels could be different from ground level, where most allergic individual reside. Until now, the effects of height of sampling on pollen concentration are not well documented. The aim of this meta-analysis was to analyse these effects using a large number of twin sampling stations.
Pollen data from 45 twin-stations Hirst-type volumetric spore traps were analyzed, with a maximum distance of 5km between the twin traps, from 25 different locations. To compare the effect of height, the mean of the daily ratio of the amounts of pollen registrered at different heights was used. The values of the lowest station were divided by the higher station. Stations between 1.5m and 50 agl were considered.
The results showed that the traps at lower height registered generally higher pollen concentration (average pollen ratio higher than 1), although the behaviour of the ratio differed per pollen type. For instance, both Poaceae and Betula showed that as the height differenc eincreased, the pollen ratio was higher up to a certain height difference when the ratio stabilizes (around 1.5). On the other hand, the standard deviation of the pollen ratio was greater for the traps closer to ground level. Therefore the height difference is a factor which explains the pollen ratio in conjunction with other variables such as the minimum height of the lower trap or the distance between the spore traps.
These findings are highly relevant to clinical practice, as the relationship between pollen exposure at ground level and monitored airborne pollen concentrations at roof-top elvel are determined. Thus, the optimal pollen monitoring height could be optimized based on these result
Infraspecific variability in baseline element composition of the epiphytic lichen Pseudevernia furfuracea in remote areas: implications for biomonitoring of air pollution
Using a temporal phylogenetic method to harmonize family- and genus-level classification in the largest clade of lichen-forming fungi
Rivaroxaban or aspirin for patent foramen ovale and embolic stroke of undetermined source: a prespecified subgroup analysis from the NAVIGATE ESUS trial
Background: Patent foramen ovale (PFO) is a contributor to embolic stroke of undetermined source (ESUS). Subgroup analyses from previous studies suggest that anticoagulation could reduce recurrent stroke compared with antiplatelet therapy. We hypothesised that anticoagulant treatment with rivaroxaban, an oral factor Xa inhibitor, would reduce the risk of recurrent ischaemic stroke compared with aspirin among patients with PFO enrolled in the NAVIGATE ESUS trial. Methods: NAVIGATE ESUS was a double-blinded, randomised, phase 3 trial done at 459 centres in 31 countries that assessed the efficacy and safety of rivaroxaban versus aspirin for secondary stroke prevention in patients with ESUS. For this prespecified subgroup analysis, cohorts with and without PFO were defined on the basis of transthoracic echocardiography (TTE) and transoesophageal echocardiography (TOE). The primary efficacy outcome was time to recurrent ischaemic stroke between treatment groups. The primary safety outcome was major bleeding, according to the criteria of the International Society of Thrombosis and Haemostasis. The primary analyses were based on the intention-to-treat population. Additionally, we did a systematic review and random-effects meta-analysis of studies in which patients with cryptogenic stroke and PFO were randomly assigned to receive anticoagulant or antiplatelet therapy. Findings: Between Dec 23, 2014, and Sept 20, 2017, 7213 participants were enrolled and assigned to receive rivaroxaban (n=3609) or aspirin (n=3604). Patients were followed up for a mean of 11 months because of early trial termination. PFO was reported as present in 534 (7·4%) patients on the basis of either TTE or TOE. Patients with PFO assigned to receive aspirin had a recurrent ischaemic stroke rate of 4·8 events per 100 person-years compared with 2·6 events per 100 person-years in those treated with rivaroxaban. Among patients with known PFO, there was insufficient evidence to support a difference in risk of recurrent ischaemic stroke between rivaroxaban and aspirin (hazard ratio [HR] 0·54; 95% CI 0·22–1·36), and the risk was similar for those without known PFO (1·06; 0·84–1·33; pinteraction=0·18). The risks of major bleeding with rivaroxaban versus aspirin were similar in patients with PFO detected (HR 2·05; 95% CI 0·51–8·18) and in those without PFO detected (HR 2·82; 95% CI 1·69–4·70; pinteraction=0·68). The random-effects meta-analysis combined data from NAVIGATE ESUS with data from two previous trials (PICSS and CLOSE) and yielded a summary odds ratio of 0·48 (95% CI 0·24–0·96; p=0·04) for ischaemic stroke in favour of anticoagulation, without evidence of heterogeneity. Interpretation: Among patients with ESUS who have PFO, anticoagulation might reduce the risk of recurrent stroke by about half, although substantial imprecision remains. Dedicated trials of anticoagulation versus antiplatelet therapy or PFO closure, or both, are warranted. Funding: Bayer and Janssen
Notes for genera – Ascomycota
Knowledge of the relationships and thus the classification of fungi, has developed rapidly with increasingly widespread use of molecular techniques, over the past 10--15 years, and continues to accelerate. Several genera have been found to be polyphyletic, and their generic concepts have subsequently been emended. New names have thus been introduced for species which are phylogenetically distinct from the type species of particular genera. The ending of the separate naming of morphs of the same species in 2011, has also caused changes in fungal generic names. In order to facilitate access to all important changes, it was desirable to compile these in a single document. The present article provides a list of generic names of Ascomycota (approximately 6500 accepted names published to the end of 2016), including those which are lichen-forming. Notes and summaries of the changes since the last edition of `Ainsworth Bisby's Dictionary of the Fungi' in 2008 are provided. The notes include the number of accepted species, classification, type species (with location of the type material), culture availability, life-styles, distribution, and selected publications that have appeared since 2008. This work is intended to provide the foundation for updating the ascomycete component of the ``Without prejudice list of generic names of Fungi'' published in 2013, which will be developed into a list of protected generic names. This will be subjected to the XIXth International Botanical Congress in Shenzhen in July 2017 agreeing to a modification in the rules relating to protected lists, and scrutiny by procedures determined by the Nomenclature Committee for Fungi (NCF). The previously invalidly published generic names Barriopsis, Collophora (as Collophorina), Cryomyces, Dematiopleospora, Heterospora (as Heterosporicola), Lithophila, Palmomyces (as Palmaria) and Saxomyces are validated, as are two previously invalid family names, Bartaliniaceae and Wiesneriomycetaceae. Four species of Lalaria, which were invalidly published are transferred to Taphrina and validated as new combinations. Catenomycopsis Tibell Constant. is reduced under Chaenothecopsis Vain., while Dichomera Cooke is reduced under Botryosphaeria Ces. De Not. (Art. 59)